THERADPOX

THERADPOX
Titre :	Optimised and novel oncolytic adenoviruses and pox viruses in the treatment of cancer: Virotherapy combined with molecular chemotherapy
Budget :	3 334 k€
Subventions :	FP6-LIFESCIHEALTH (2 411 k€)
Sous-programme :	LSH-2004-1.2.4-7
Type de contrat :	Specific Targeted Research Project
Début :	1er décembre 2005
Fin :	30 novembre 2008
Retour à la liste des projets du programme

THERADPOX est l'acronyme du projet européen Optimised and novel oncolytic adenoviruses and pox viruses in the treatment of cancer: Virotherapy combined with molecular chemotherapy, qui a pour référence sur le service CORDIS 18700.

English description

Note : Les objectifs suivants sont repris de la fiche du projet sur Cordis

Objective

Cancer is today the second cause of disease-induced mortality worldwide. Among innovative treatments for cancer, virotherapy holds great promise. Virotherapy exploits an intrinsic feature of the lifecycle of oncolytic viruses (OVs): replication and sprea ding exclusively in tumour cells leading to their destruction, while not affecting normal cells. Clinical studies have demonstrated the safety and feasibility of this approach, but have shown only minimal therapeutic efficacy. Synergistic effects of comb ination treatments of OVs with chemo- and radiation therapy have been observed. Nevertheless, this approach still leaves patients subjected to the toxic adverse effects of chemotherapy and radiation. Thus, an unmet need exists for the improvement of curr ent and the development of new treatment platforms leading to a significant increase in cure rates. Owing to their inherent strong oncolytic potency and safety record, pox virus and adenovirus based vectors have been chosen to pursue the goal of the THER ADPOX project: to improve the safety and therapeutic efficacy of OVs in vivo. Novel and improved OVs will be engineered which, in vivo i) specifically target colorectal, pancreatic and ovarian cancer cells, ii) replicate exclusively in cancer cells, iii) are armed with therapeutic genes rendering only tumour cells sensitive to chemotherapy, and iv) widely spread within the tumour to permit total tumour eradication. Through the multidisciplinary workplan proposed and the strong and complementary experti se of the 10 European partners involved, the THERADPOX project will i) generate advanced knowledge which could be translated towards a safer cancer treatment with an increased therapeutic index, ii) contribute to improve the quality of life of cancer pat ients by fewer treatments with no toxic side effects, iii) lead to the proposal of new guidelines and standards for the development of OVs, and iv) strengthen the competitiveness of Europe.

 

Les partenaires du projet

Coordinateur du projet

• Transgene S.A. - Illkirch-Graffenstaden (Alsace, France)

Partenaires

• Newlab S.A.R.L. - Villers-lès-Nancy (Lorraine, France) - Contact : Abdelmjid Boussetta
• Delsitech LTD - Turku (Finlande)
• Université d'Helsinki - Helsinki (Finlande)
• Paul-Ehrlich-Institut - Langen (Allemagne)
• Acies SAS - Lyon (Rhône-Alpes, France)
• Institut national de la recherche agronomique - Castanet-Tolosan (Midi-Pyrénées, France)
• Institut català d'oncologia - Barcelone (Espagne)
• The university court of the university of St Andrews - St Andrews (Royaume-Uni)
• Oncotest GMBH, Institute for experimental oncology - Fribourg (Allemagne)

Financement

• Coût total du projet : 3 334 907 €
• Subvention de la Commission européenne (programme FP6-LIFESCIHEALTH) : 2 411 006 €

Dates importantes

• Date de début : 1^er décembre 2005
• Date de fin : 30 novembre 2008

Documents

Final Report - THERADPOX (Optimised and novel oncolytic adenoviruses and pox viruses in the treatment of cancer: Virotherapy combined with molecular chemotherapy)

Voir aussi

Liens externes

• Le site de Transgene S.A.